#pharma - Techseriesinsight

June 17, 2025
PRNewswire
Healthcare

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy...

April 29, 2025
PRNewswire
Biotechnology

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced that, effective April 20, 2025, the Board of Directors has appointed Sumant Ramachandra, M.D., Ph.D. as Chief...

April 11, 2025
PRNewswire
Healthcare

OrderlyMeds’ Response to Eli Lilly’s Cease-and-Desist Letter

On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response. Prescribers and pharmacists have been taking care of...

April 10, 2025
PRNewswire
Biotechnology

South Rampart Pharma Strengthens Board with Appointment of Ochsner Health CEO Pete November

South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage biotechnology company advancing best-in-class, non-opioid pain therapeutics, today announced the appointment of Pete November, CEO of Ochsner Health, to...

April 1, 2025
PRNewswire
Healthcare

ixlayer and Ipsos’ “ixInsights 2025” Study Reveals Consumer Expectations for Digital Health and Pharma’s Role in Enhancing Patient Experience

ixlayer, a leading cloud-based healthtech platform, with Ipsos, a global leader in market research, have released findings from the inaugural research report, “ixlayer ixInsights 2025: Pharma’s Role in Improving the Health...